Could a common antidepressant boost cancer immunotherapy?
NCT ID NCT07174947
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the antidepressant fluoxetine (Prozac) to standard immunotherapy can improve tumor control and survival in 240 people with advanced liver or gallbladder cancer who also have depression or anxiety. Participants will receive either fluoxetine or a placebo alongside their immunotherapy. The goal is to see if treating mood symptoms can also enhance the anti-cancer immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluoxetine (an antidepressant)
What this could lead to
If it works, this could point toward a way to improve immunotherapy effectiveness and survival in patients with advanced liver or gallbladder cancer who also have depression or anxiety.
What could go wrong
This is a Phase 2 trial, so it is still early. The benefit of fluoxetine for cancer control is not proven, and side effects from the combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOBILIARY MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••